Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chimigen Hepatitis C Vaccine
- Development stage
- Preclinical
- Lead developer
- Chimigen Biosciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
Chimigen Hepatitis C Vaccine is a therapeutic and preventive vaccine candidate developed using the proprietary Chimigen platform. The vaccine consists of recombinant fusion proteins that combine specific Hepatitis C Virus (HCV) antigens—such as NS3, Core, E1, and E2—with a chimeric delivery moiety designed to target and activate dendritic cells. This platform technology is engineered to enhance the uptake and processing of viral antigens by antigen-presenting cells, thereby stimulating a robust and multi-functional cellular immune response. Specifically, it aims to induce high levels of CD4+ and CD8+ T-cells, which are critical for the clearance of chronic HCV infection and the establishment of protective immunity. Originally developed by Chimigen Biosciences, the program and platform were subsequently acquired by PDS Biotechnology.
- Other names
- Chimigen HCV vaccinePDS Biotechnology Hepatitis C Vaccine
02
Targets
FcγRII (Fc gamma receptor II)HCV E1 (Hepatitis C virus envelope glycoprotein E1)HCV E2 (Hepatitis C virus envelope glycoprotein E2)NS3 (Dengue virus NS3 protein)Core (Hepatitis C virus core protein)MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on Chimigen Hepatitis C Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chimigen Hepatitis C Vaccine.